FDA proposes clinical trial, endpoint considerations in MDS drug development guidance
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesClinical Trials Regulation GuidancePharmaceuticalsPreclinicalRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)